Thorsten Hage

BioCrea (Germany) — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index843citations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phosphodiesterase function and regulation(10), Cholinesterase and Neurodegenerative Diseases(4), Immune Response and Inflammation(3), T-cell and B-cell Immunology(2), Nerve injury and regeneration(2)

Publications16 total

Phosphodiesterase 2 Inhibitors Promote Axonal Outgrowth in Organotypic Slice Co-Cultures
Neurosignals·2012· 14 citedOpen Access
Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801
Behavioural Brain Research·2012· 87 cited
Novel triazines as potent and selective phosphodiesterase 10A inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 26 citedOpen Access
Highly Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitors
Journal of Medicinal Chemistry·2011· 72 citedOpen Access
P.1.g.012 The pro-cognitive profile of the phosphodiesterase 2A inhibitor BCR909 highlights its utility as a novel treatment for diseases with cognitive decline
European Neuropsychopharmacology·2011· 1 cited
P.1.c.021 Effect of phosphodiesterase 2A inhibition on striatal dopamine in a microdialysis study and its reflection in dopamine-associated effects in animal models
European Neuropsychopharmacology·2011
Inhibitors of the phosphodiesterase 2 increased axonal fibre growth in a dopaminergic organotypic ex vivo slice co-culture model
BMC Pharmacology·2011Open Access
P.3.d.005 Activity of phosphodiesterase 10A inhibitors in a novel animal model of negative symptoms of schizophrenia
European Neuropsychopharmacology·2010
Discovery of Imidazo[1,5-<i>a</i>]pyrido[3,2-<i>e</i>]pyrazines as a New Class of Phosphodiesterase 10A Inhibitiors
Journal of Medicinal Chemistry·2010· 63 citedOpen Access
P.2.d.002 The phosphodiesterase 2 inhibitor BTT5001 demonstrates anxiolytic, anti-depressive and pro-cognitive efficacy in vivo
European Neuropsychopharmacology·2009
Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
Journal of Pharmacology and Experimental Therapeutics·2009· 266 cited
PDE10 INHIBITION FOR THE TREATMENT OF SCHIZOPHRENIA
Schizophrenia Research·2008
RNA-Based Drug Screening Using Automated RNA Purification and Real-time RT-PCR1
SLAS DISCOVERY·2004· 4 citedOpen Access
Crystal Structure of the Interleukin-4/Receptor α Chain Complex Reveals a Mosaic Binding Interface
Cell·1999· 220 citedOpen Access
Crystals of a 1 : 1 complex between human interleukin‐4 and the extracellular domain of its receptor α chain
European Journal of Biochemistry·1998· 9 citedOpen Access
Global and Local Determinants for the Kinetics of Interleukin‐4/Interleukin‐4 Receptor α Chain Interaction
European Journal of Biochemistry·1996· 81 citedOpen Access

Frequent Co-authors

Barbara Langen(8), Ute Egerland(8), Nicholas J. Brandon(6), Karen L. Marquis(5), Hans Stange(5), Hans‐Joachim Lankau(5), Norbert Hoefgen(5), Michael S. Malamas(4), Rachel L. Navarra(3), Radka Graf(3), Julie Brennan(3), Walter Sebald(3), Rudolf Schindler(3), Christian Grunwald(3), Boyd L. Harrison(3), Thomas Kronbach(3), Menelas N. Pangalos(3), Peter Reinemer(2), Yike Ni(2), James Erdei(2)